SCHEMBL31516644

SCHEMBL31516644

COc1cc(C(=O)NS(=O)(=O)c2cc(Br)ccc2OC)ccc1Cn1cccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLA P06280 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ KAT7 O95251 5/20 0.44
▸ KAT6A Q92794 5/20 0.44
▸ KAT6B Q8WYB5 4/20 0.44
▸ KAT5 Q92993 1/20 0.44
▸ KAT8 Q9H7Z6 1/20 0.44
▸ ALPL P05186 2/20 0.43
▸ SMPD1 P17405 1/20 0.43
▸ MAPT P10636 2/20 0.43
▸ HDAC6 Q9UBN7 2/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ PTGER1 P34995 1/20 0.42
▸ PTGER4 P35408 1/20 0.42
▸ DRD3 P35462 1/20 0.42
▸ PTGER3 P43115 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31172604 0.90 KAT7 (0.44) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516757 0.89 KAT7 (0.54) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516722 0.89 KAT7 (0.44) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516772 0.89 KAT7 (0.44) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31172714 0.89 KAT7 (0.52) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31691246 0.88 ALPL (0.43) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516806 0.88 KAT7 (0.42) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516602 0.88 KAT6A (0.42) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516668 0.87 ALPL (0.44) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516610 0.85 KAT7 (0.44) KAT7KAT6AKAT6BKAT5KAT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B GLA 1691/4885SMN1; SMN2 1852/4885ALDH1A1 2242/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B GLA 1691/4885SMN1; SMN2 1852/4885ALDH1A1 2242/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B GLA 1993/4885SMN1; SMN2 3098/4885ALDH1A1 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback